Anti-MAFbx antibody [EPR9148(2)] is a rabbit recombinant monoclonal antibody designed to detect Fbx32, also known as Atrogin-1, a muscle-specific E3 ubiquitin ligase involved in muscle atrophy. Validated for ICC/IF and western blotting. Suitable for human, mouse, and rat samples.
- Cited in over 100 publications
- Using biophysical QC, antibody identity is confirmed at a molecular level for unrivaled batch-batch consistency
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | IHC-P | ICC/IF | |
---|---|---|---|
Human | Tested | Not recommended | Tested |
Mouse | Tested | Not recommended | Expected |
Rat | Tested | Not recommended | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 - 1/2000 | Notes - |
Species Rat | Dilution info 1/1000 - 1/2000 | Notes - |
Species Human | Dilution info 1/1000 - 1/2000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/200 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins during skeletal muscle atrophy. Recognizes TERF1.
F-box only protein 32, Atrogin-1, Muscle atrophy F-box protein, MAFbx, FBXO32
Anti-MAFbx antibody [EPR9148(2)] is a rabbit recombinant monoclonal antibody designed to detect Fbx32, also known as Atrogin-1, a muscle-specific E3 ubiquitin ligase involved in muscle atrophy. Validated for ICC/IF and western blotting. Suitable for human, mouse, and rat samples.
- Cited in over 100 publications
- Using biophysical QC, antibody identity is confirmed at a molecular level for unrivaled batch-batch consistency
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
All lanes: Western blot - Anti-Fbx32 antibody [EPR9148(2)] (ab168372) at 1/1000 dilution
Lane 1: Mouse muscle at 20 µg
Lane 2: Rat muscle at 20 µg
Predicted band size: 42 kDa
Observed band size: 42 kDa
Immunofluorescent staining of A673 cells (fixed in 4% PFA) using purified ab168372 at a dilution of 1/200. An Alexa Fluor® 555 goat anti-rabbit (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 555) preadsorbed ab150082) was used at a dilution of 1/500 and the cells were counter-stained with DAPI. The negative control is shown in the bottom right hand panel - for the negative control, purified ab168372 was used at a dilution of 1/200 followed by an Alexa Fluor® 488 goat anti-mouse antibody at a dilution of 1/400.
Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
All lanes: Western blot - Anti-Fbx32 antibody [EPR9148(2)] (ab168372) at 1/1000 dilution
All lanes: Human skeletal muscle at 10 µg
All lanes: HRP anti-rabbit IgG (specific to non-reduced IgG) at 1/1000 dilution
Predicted band size: 42 kDa
Observed band size: 42 kDa
Immunofluorescent analysis of A673 cells labeling Fbx32 with ab168372 at 1/250 dilution.
All lanes: Western blot - Anti-Fbx32 antibody [EPR9148(2)] (ab168372) at 1/1000 dilution
Lane 1: mouse heart lysate at 10 µg
Lane 2: rat muscle lysate at 10 µg
All lanes: Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 42 kDa
Image collected and cropped by CiteAb under a CC-BY license from the publication
Fbx32 western blot using anti-Fbx32 antibody [EPR9148(2)] ab168372. Publication image and figure legend from Zeng, X., Chen, S., et al., 2017, Oncotarget, PubMed 29069832.
ab168372 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab168372 please see the product overview.
AG/UnAG attenuates ubiquitin E3 legases expression in co-cultured myotubes(A) Western blot of atrogin-1, MuRF1 and GAPDH in C2C12 myotubes. (B) Quantification of atrogin-1 was normalized to GAPDH. Significant differences were detected between CO and any NC groups (#P < 0.001), between CO and CO+AG/UnAG groups (*P = 0.001, P < 0.001; respectively), by one-way ANOVA followed by Tukey test. (C) Quantification of MuRF1 was normalized to GAPDH. Significant differences were detected between CO and any NC groups (#P = 0.002), between CO and CO+AG/UnAG groups (*P = 0.015, P = 0.037; respectively), by one-way ANOVA followed by Tukey test. (D) The levels of atrogin-1 mRNA in C2C12 myotubes. mRNA levels were normalized to GAPDH. Significant differences were detected between NC and CO groups (#P = 0.024), between CO and CO+AG/UnAG groups (*P = 0.034, P = 0.033; respectively), by one-way ANOVA followed by Dunnett's T3 test. (E) The levels of MuRF1 mRNA in C2C12 myotubes. mRNA levels were normalized to GAPDH. Significant differences were detected between NC and CO groups (#P = 0.006, P = 0.006; P = 0.007 respectively), between CO and CO+AG groups (*P = 0.016, P = 0.012), by one-way ANOVA followed by Tukey test. Data are represented as mean ± SD.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com